HROW

Harrow Inc

Add to Watchlist

Advanced Chart

24.815

-0.310(-1.230%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

24.8914

Open

24.8914

VWAP

24.83

Vol

35.50K

Mkt Cap

922.08M

Low

24.710

Amount

881.31K

EV/EBITDA(TTM)

53.14

Total Shares

35.38M

1.12B

EV/OCF(TTM)

533.83

P/S(TTM)

4.41

Harrow, Inc., formerly Harrow Health, Inc., is a eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides comprehensive portfolio of prescription and non-prescription pharmaceutical products. The Company offers pharmaceutical products for ophthalmic surgeries in the United States, as well as medications prescribed to treat patients managing chronic and acute eye conditions, such as dry eye disease, glaucoma, allergies, infections, and other ophthalmic inflammatory conditions. It serves over 10,000 doctors, hospitals, and ambulatory service centers (ASCs) and regularly ship to over 1,500 institutional accounts each month.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

92.68M

+38.67%

74.54M

+51.32%

65.38M

+33.59%

Estimates Revision

The market is revising Downward the revenue expectations for Harrow, Inc. (HROW) for FY2025, with the revenue forecasts being adjusted by -7.3% over the past three months. During the same period, the stock price has changed by -18.83%.

Revenue Estimates for FY2025

Revise Downward

-7.3%

In Past 3 Month

Stock Price

Go Down

-18.83%

In Past 3 Month

4 Analyst Rating

137.76% Upside

Wall Street analysts forecast HROW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HROW is 59.00 USD with a low forecast of 55.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

137.76% Upside

Current: 24.815

Low

55.00

Averages

59.00

High

65.00

137.76% Upside

Current: 24.815

Low

55.00

Averages

59.00

High

65.00

B. Riley Securities

Mayank Mamtani

Strong Buy

Maintains

$69 → $65

2025-04-01

Reason

B. Riley Securities

Mayank Mamtani

Price Target

$69 → $65

2025-04-01

Maintains

Strong Buy

Reason

B. Riley analyst Mayank Mamtani lowered the firm's price target on Harrow to $65 from $69 and keeps a Buy rating on the shares following the Q4 report. The firm believes the "significant headroom" to multi-year volume growth for all three of the company's brands remains underappreciated, particularly as Harrow's commercial teams make progress. However, the firm acknowledges Harrow's quarterly product business "lumpiness."

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$57

2025-03-31

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$57

2025-03-31

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$57

2025-03-18

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$57

2025-03-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Initiates

$57

2025-02-06

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$57

2025-02-06

Initiates

Strong Buy

Reason

Craig-Hallum

Chase Knickerbocker

Strong Buy

Maintains

$45 → $65

2024-10-04

Reason

Craig-Hallum

Chase Knickerbocker

Price Target

$45 → $65

2024-10-04

Maintains

Strong Buy

Reason

Craig-Hallum analyst Chase Knickerbocker raised the firm's price target on Harrow to $65 from $45 and keeps a Buy rating on the shares. The relaunch of Triesence is expected to be highly accretive to the company, as there are substantial commercial synergies with their commercial strategy for Iheezo, the analyst tells investors in a research note. The firm is now modeling Triesence contribution in Q4, which previously began contribution in 1Q25 in its model.

Lake Street

Brooks O'Neil

Strong Buy

Maintains

$45 → $55

2024-10-04

Reason

Lake Street

Brooks O'Neil

Price Target

$45 → $55

2024-10-04

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Harrow Inc (HROW.O) is 45.19, compared to its 5-year average forward P/E of 62.89. For a more detailed relative valuation and DCF analysis to assess Harrow Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

62.89

Current PE

45.19

Overvalued PE

335.25

Undervalued PE

-209.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

10.39

Current EV/EBITDA

12.88

Overvalued EV/EBITDA

43.47

Undervalued EV/EBITDA

-22.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.22

Current PS

3.19

Overvalued PS

4.39

Undervalued PS

2.05